Second Edition

CLINICAL AND TRANSLATIONAL SCIENCE:

PRINCIPLES OF HUMAN RESEARCH







Edited by
David Robertson
Gordon H. Williams

AP

Clinical and Translational Science

Principles of Human Research

Second Edition

Edited by

David Robertson MD
Director, Clinical & Translational Research Center, Elton Yates Professor of Medicine, Pharmacology and Neurology, Vanderbilt University, Nashville, TN, United States

Gordon H. Williams MD
Chief, Hormonal Mechanisms of Cardiovascular Injury Laboratory, Brigham and Women's Hospital, and Professor of Medicine, Harvard Medical School, Boston, MA, United States

ELSEVIER

AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD • PARIS
SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library

ISBN: 978-0-12-802101-9

Publisher: Mica Haley
Acquisition Editor: Mica Haley
Editorial Project Manager: Lisa Eppich
Production Project Manager: Laura Jackson
Designer: Victoria Pearson Esser

Typeset by TNQ Books and Journals

List of Contributors

Salim Abdool Karim University of KwaZulu–Natal, Durban, South Africa; Columbia University, New York, NY, United States

Donna K. Arnett University of Kentucky, Lexington, KY, United States

James R. Baker, Jr. University of Michigan, Ann Arbor, MI, United States

Seema Basu Partners HealthCare Innovation, Cambridge, MA, United States

Stacey Berg Texas Children's Hospital, Houston, TX, United States

Gordon R. Bernard Vanderbilt University School of Medicine, Nashville, TN, United States

Italo Biaggioni Vanderbilt University, Nashville, TN, United States

Lisa Bomgaars Texas Children's Hospital, Houston, TX, United States

Robert A. Branch University of Pittsburgh, Pittsburgh, PA, United States

Nancy J. Brown Vanderbilt University School of Medicine, Nashville, TN, United States

Robert M. Califf U.S. Food and Drug Administration, Silver Spring, MD, United States

Henry C. Chueh Massachusetts General Hospital, Boston, MA, United States

Steven A. Claas University of Alabama at Birmingham, Birmingham, AL, United States

William F. Crowley, Jr. Massachusetts General Hospital, Boston, MA, United States

Joann Data Data Consulting, Sparta, TN, United States

George D. Demetri Dana-Farber Cancer Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, MA, United States

Zeruesenay Desta Indiana University, Indianapolis, IN, United States

Ruth M. Dunne Harvard Medical School, Boston, MA, United States

Luigi Ferrucci NIA, Baltimore, MD, United States

David A. Flockhart Indiana University, Indianapolis, IN, United States

Audrey Gassman U.S. Food and Drug Administration, Silver Spring, MD, United States

Rashmi Gopal-Srivastava National Institutes of Health, Bethesda, MD, United States

Glenn Gormley Daiichi Sankyo Inc., Edison, NJ, United States

Steven Grinspoon Harvard Medical School, Boston, MA, United States

Stephen C. Groft National Institutes of Health, Bethesda, MD, United States

Katherine E. Hartmann Vanderbilt University School of Medicine, Nashville, TN, United States

Elizabeth Heitman Vanderbilt University School of Medicine, Nashville, TN, United States

Christopher D. Herrick Massachusetts General Hospital, Boston, MA, United States

Hylton V. Joffe U.S. Food and Drug Administration, Silver Spring, MD, United States

Kush Kapur Harvard Medical School, Boston, MA, United States

Mark D. Kellogg Boston Children's Hospital, Boston, MA, United States

Richard B. Kim The University of Western Ontario, London, ON, Canada

Bruce R. Korf University of Alabama at Birmingham, Birmingham, AL, United States

Greg Koski Harvard Medical School, Boston, MA, United States; Massachusetts General Hospital, Boston, MA, United States

Ronald L. Krall University of Pittsburgh, Pittsburgh, PA, United States; GlaxoSmithKline

Jessica Lasky-Su Harvard Medical School and Brigham and Women's Hospital, Boston, MA, United States

Shawn N. Murphy Massachusetts General Hospital, Boston, MA, United States

Christine Nguyen U.S. Food and Drug Administration, Silver Spring, MD, United States

Ailbhe C. O'Neill Harvard Medical School, Boston, MA, United States

Daniel J. Pallin Harvard Medical School, Boston, MA, United States

James Quinn Stanford University, Stanford, CA, United States

Keren Regev Harvard Medical School, Boston, MA, United States

Uwe E. Reinhardt Princeton University, Princeton, NJ, United States

Todd W. Rice Vanderbilt University School of Medicine, Nashville, TN, United States

Rose Marie Robertson American Heart Association, Dallas, TX, United States

David Robertson Clinical & Translational Research Center, Elton Yates Professor of Medicine, Pharmacology and Neurology, Vanderbilt University, Nashville, TN, United States

Dan M. Roden Vanderbilt University Medical Center, Nashville, TN, United States

Angela J. Rogers Stanford University, Stanford, CA, United States

Daniel E. Salazar EMS Pharma, Hortolàndia, SP, Brazil

J. Sanford Schwartz University of Pennsylvania, Philadelphia, PA, United States

Alan F. Schatzberg Stanford University, Stanford, CA, United States

Ellen W. Seely Harvard Medical School, Boston, MA, United States

Joe V. Selby Patient-Centered Outcomes Research Institute, Washington, DC, United States

César Serrano Vall d'Hebron University Hospital, Barcelona, Spain

Donald C. Simonson Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States

Ann R. Stark Monroe Carell Jr. Children's Hospital, Nashville, TN, United States

Stephanie Studenski NIA, Baltimore, MD, United States

Clare M. Tempany Harvard Medical School, Boston, MA, United States

Marcia A. Testa Harvard T. H. Chan School of Public Health, Boston, MA, United States

Thommey P. Thomas University of Michigan, Ann Arbor, MI, United States

Rommel G. Tirona The University of Western Ontario, London, ON, Canada

Stephanie L. Tomasic The Pitt-Bridge: Gateway to Success, Pittsburgh, PA, United States

Suzie Upton American Heart Association, Dallas, TX, United States

Sten H. Vermund Vanderbilt University, Nashville, TN, United States

Brent B. Ward University of Michigan, Ann Arbor, MI, United States

Howard L. Weiner Harvard Medical School, Boston, MA, United States

Scott T. Weiss Harvard Medical School, Boston, MA, United States; Partners HealthCare Personalized Medicine, Boston, MA, United States; Channing Division of Network Medicine, Boston, MA, United States

Danielle M. Whicher Patient-Centered Outcomes Research Institute, Washington, DC, United States

Gordon H. Williams Hormonal Mechanisms of Cardiovascular Injury Laboratory, Brigham and Women's Hospital, and Professor of Medicine, Harvard Medical School, Boston, MA, United States

Mary Woolley Research!America, Alexandria, VA, United States

Nathalie K. Zgheib American University of Beirut, Beirut, Lebanon

Contents

List of Contributors xix

Section I
Fundamental Principles

1. Introduction to Clinical Research

Gordon H. Williams and David Robertson

Historical Background 3
Organization of This Book 6
Note 6
References 7

2. Patient-Oriented Research

Ellen W. Seely and Steven Grinspoon

Introduction 9
Types of Patient-Oriented Research 10
Observational Studies 11
Mechanism Studies 11
Therapeutic Studies 12
Clinical Trials 12
The Role of Patient-Oriented Research in Translational Research 14
Interaction of Basic Science and Patient-Oriented Research 14
Interaction of Patient-Oriented Research and the Community 15
The Role of the Patient in Patient-Oriented Research 15
Sequence of Investigation 16
Hypothesis Generation 16
Designing the Study 16
Feasibility 19
Confounding 19
Subject Safety and the Institutional Review Board 19
Database Development 20
Data Analysis Plan 20
Tools of the Patient-Oriented Researcher 20
Funding for Patient-Oriented Research 21
Conclusions 21
References 21

3. Clinical Trials

Robert M. Califf

Introduction 26
History 26
Phases of Evaluation of Therapies 26
Critical General Concepts 27
Purposes of Clinical Trials 27
Validity 27
Generalizability 28
Trade-off of Validity and Generalizability 28
Expressing Clinical Trial Results 29
Concepts Underlying Trial Design 30
Treatment Effects Are Modest 31
Qualitative Interactions Are Uncommon 32
Quantitative Interactions Are Common 32
Unintended Biological Targets Are Common 32
Interactions Among Therapies Are Not Predictable 33
Long-Term Effects May Be Unpredictable 33
General Design Considerations 33
Pragmatic Versus Explanatory 34
Entry Criteria 34
Data Collection Instrument 34
Ancillary Therapy and Practice 35
Multiple Randomization 35
Adaptive Trial Designs 35
Legal and Ethical Issues 36
Medical Justification 36
Groups of Patients Versus Individuals 36
Blinding 37
Endpoint Adjudication 37
Intensity of Intervention 38
Surrogate Endpoints 38
Conflict of Interest 38
Special Issues With Device Trials 39
Hypothesis Formulation 40
Primary Hypothesis 40
Secondary and Tertiary Hypotheses 40
Intention to Treat 41

Publication Bias 41
Statistical Considerations 41
Type I Error and Multiple Comparisons 41
Type II Error and Sample Size 41
Noninferiority 42
Sample Size Calculations 42
Metaanalysis and Systematic Overviews 43
Understanding Covariates and Subgroups 44
Therapeutic Truisms 44
Study Organization 45
Executive Functions 45
Coordinating Functions 47
Supporting Functions 47
Integration Into Practice 49
The Future 49
Acknowledgment 50
References 50

4. Introduction to Epidemiology

Donna K. Arnett and Steven A. Claas

Introduction: Definition and Role of Epidemiology 54
Measuring Occurrence of Disease 55
Defining Diseases, Outcomes, and Other Health-Related States or Events 55
Calculating Incidence and Prevalence 56
Measuring Risk and Association 57
Calculating Risk 57
Quantifying Associations 58
Types of Epidemiological Studies 59
Cross-sectional Studies 59
Cohort Studies 59
Case–Control Studies 60
Hybrid Study Designs 61
Study Design: Summary 62
Threats to Validity and Reliability 62
Defining and Measuring Threats to Validity and Reliability 62
Estimating and Avoiding Threats to Validity 64
Estimating and Avoiding Threats to Reliability 65
Moving From Association to Causation 65
Clinical Epidemiology 67
Sex, Gender, Race, and Ethnicity in Epidemiology 67
Conclusion 68
Acknowledgment 68
References 68
Recommended Resources 69

5. The Patient-Centered Outcomes Research Institute: Current Approach to Funding Clinical Research and Future Directions

Joe V. Selby and Danielle M. Whicher

Introduction: The Patient-Centered Outcomes Research Institute 72
Patient-Centered Comparative Effectiveness Research 73
Defining Patient-Centered Comparative Effectiveness Research 73
Establishing National Priority Areas for Patient-Centered Comparative Effectiveness Research 74
Patient and Stakeholder Engagement in Research 74
PCORI's Efforts to Engage Patients and Stakeholders in Setting Research Priorities and Selecting Research Applications for Funding 74
Engaging Patients and Stakeholders in Conducting Research 75
PCORI's Rubric for Patient and Stakeholder Engagement 76
Methodology Standards for Patient-Centered Comparative Effectiveness Research 77
PCORI's Methodology Committee 77
PCORI's Methodology Standards 77
Pragmatic Research 78
Defining Features of Pragmatic Research 78
PCORI's Efforts to Support Pragmatic Research 78
Study Designs for Pragmatic Research and Other Comparative Effectiveness Research 80
Integrating Research Into the Learning Health-Care System 81
The Case for Locating Clinical Research Within Health-Care Delivery 81
Electronic Health Records and Insurance Claims Data 81
The Use of Clinical Registries in Research 82
The National Patient-Centered Outcomes Research Network 83
Conclusion: Vision of Clinical Research in the 21st Century 85
Glossary 86
List of Acronyms and Abbreviations 86
References 87

6. Health-Care Technology Assessment (HTA)

Uwe E. Reinhardt

Summary 92
Introduction 92
The Evaluation of New Medical Technology: The Producer's Perspective 93
Private, Investor-Owned Producers of New Medical Technology 93
Public Producers of New Technology 95
The Evaluation of New Medical Technology: The End User's Perspective 95
The Ethical Precepts Driving Markets 96
The Implications of the Market Approach for the Producers of New Medical Technology 96
The Evaluation of New Medical Technology: Society's Perspective 97
The General Framework for Technology Assessment in Health Care 97
Defining Net Incremental Benefits 98
Whose Costs and Benefits? 99
The Issue of Discounting Costs and Benefits 99
Should Benefits Be Age Adjusted? 100
Cost–Benefit, Cost-Effectiveness, and Cost–Utility Analysis 100
Cost–Benefit Analysis 100
Cost-Effectiveness Analysis 102
Cost–Utility Analysis: Quality-Adjusted Life Years and Disability-Adjusted Life Years Lost 102
Can One Ever Avoid Putting Monetary Values on Health Benefits? 106
Comparing Alternative Treatments 106
Cost-Effectiveness Analysis and Cost–Utility Analysis and National Health Policy 107
Unresolved Controversies on Economic Valuations in Health Care 108
Methodological Issues 108
Objections on Ethical Grounds 108
Objection on Commercial Grounds 109
References 109

7. Health Services Research: Translating Discovery and Research Into Practice and Policy

J. Sanford Schwartz

Introduction 112
What Is Health Services Research and What Are Its Goals? 112
Assessing Medical Interventions: Outcomes, Effectiveness, and Cost-Effectiveness 113
Assessing Medical Interventions 114
Medical Decision-Making 117
Quality Medical Care 123
Variations in Care 124
Medical Errors and Safety 127
Disparities and Inequities of Care 130
Quality Management and Improvement 131
Conclusions 132
References 132

Section II Approaches

8. Measurement of Biological Materials

Mark D. Kellogg

Introduction 138
Immunoassays and Immunochemistry 138
Background 138
Basic Principles 138
Enzyme Immunoassays 139
Other Types of Immunoassays 140
Characterization of Immunoassay Performance 142
Mass Spectrometry and Chromatography 142
Background 142
Basic Principles 142
Gas Chromatography 143
Liquid Chromatography 144
Mass Spectrometry 145
Mass Analyzers and Modes of Analysis 146
Mass Spectrometry and Clinical Research 148
Genomics 148
Background 148
Basic Principles and Methodological Considerations 148
Summary and Applications to Clinical and Translational Research 149
Proteomics, Lipidomics, Metabolomics, and Multiomics 149
Background 149
Basic Principles and Methodological Considerations 151
Applications of -Omic Analysis 152
Summary and Applications to Clinical and Translational Research 153
Conclusion 153
References 153

9. Imaging Tools in Clinical Research: Focus on Imaging Technologies

Ruth M. Dunne, Ailbhe C. O'Neill and Clare M. Tempany

Introduction 158
Imaging Technologies 158
Overview 158
Computed Tomography 158
Magnetic Resonance Imaging 162
Ultrasound 167
Nuclear Medicine 170
Optical Imaging 173
Conclusion 176
References 176

10. Imaging Tools in Human Research: Focus on Image-Guided Intervention

Ruth M. Dunne, Ailbhe C. O'Neill and Clare M. Tempany

Introduction 182
Image-Guided Biopsy 182
Breast 182
Lung 182
Prostate 183
Image-Guided Therapy 184
Ablation 184
Focused Ultrasound 185
Targeted Drug Delivery 187
Hybrid Operating Room 187
Treatment Planning in Radiation Oncology—The Role of the Radiologist 188
Conclusion 188
References 188

11. Nanotechnology in Clinical and Translational Research

James R. Baker Jr., Brent B. Ward and Thommey P. Thomas

Introduction and Historical Perspective 191
History of Nanotechnology in Medicine 191
Rationale for Nanotechnology in Medicine and Research 192
Nanotechnology in Basic Research Applications Supporting Clinical Translation 192
Knockout of Specific Biomarkers and Genes 192
Structural Analysis of Proteins 193
Artificial Substrates to Examine Cellular Functions 193
Clinical Applications of Nanotechnology for Research 193
Nanoparticle-Targeted Drug Delivery 193
Nanoparticles for Analytical Techniques 199
Conclusion and Future Directions in Nanomedicine 203
References 203

12. The Use of Questionnaires and Surveys

Marcia A. Testa and Donald C. Simonson

Introduction 207
The Practice of Questionnaire and Survey Measurement 208
The Emergence of Questionnaire and Survey Measurement in Clinical Investigation 208
Items, Scales, Questionnaires, and Instruments 210
The Role of Psychometrics 211
Questionnaires Used to Assess Patient-Reported Outcomes 211
Choosing the Appropriate Questionnaire 215
The Different Types of Questionnaires 217
Types of Health Outcomes Assessed Using Questionnaires 218
Evaluating Questionnaires and Survey Instruments 218
Reliability, Validity, Sensitivity, and Responsiveness 220
Item Response Theory, Dynamic Questionnaires, and Computer Adaptive Testing 222
Statistical and Analysis Considerations 223
Analysis and Interpretation of Multiple, Hierarchical, and Correlated Scales 223
Interpreting a Minimal Clinically Important Difference 223
Summary and Conclusions 224
Glossary 224
List of Acronyms and Abbreviations 225
References 225

13. Information Technology

Shawn N. Murphy, Henry C. Chueh and Christopher D. Herrick

Introduction 228
Clinical Data Repositories 228
Harnessing the Clinical Enterprise as a Data Source 228

Clinical Data Repositories: A Problematic Data Source 228
The Expanding Use of Preresearch Clinical Registries 228
Design for Research Data Warehouses 229
Metadata 230
Aggregating Data 232
Work Processes 233
Considerations for Warehousing Genomic Data 233
Research Data Warehouse Versus Population Management Databases 234
Information Technology Support of Participant Recruitment 235
Strategies for Participant Recruitment 235
Reaching Only Interested Participants 235
Identifying Only Eligible Participants 235
Principles of Data Collection 236
Automation and the Human Element 236
Data Validity: Capturing Data With Consistent Metadata 236
Continuous Quality Assurance 236
"Stand-alone" Electronic Data Capture 236
Integration With Clinical Documentation 236
Problems With Integrated Models 237
Data Standards 238
Use of Web Standards 238
Content Standards 239
Clinical Trial Management Systems 239
Publicly Available Databases 239
Biomedical Literature 240
Clinical Trials and Research 240
Evidence-Based Medicine 240
The Growing Impact of Big Data and the Cloud 240
Conclusion 241
References 241

14. Principles of Biostatistics

Kush Kapur

Introduction 243
Types of Data 244
Descriptive Statistics 245
Central Limit Theorem 246
A Cautionary Note on the Application of Central Limit Theorem 247
Testing and Summarizing Relationship Between Two Variables 248
p-Value and Confidence Intervals 248
Type I and II Error Rates 249
Baseline Comparisons and Primary Outcome Analysis 249
Generalized Linear Models 251
Linear Regression Model for the Continuous Data 251
Logistic Regression Model for the Binary Data 252
Survival Analysis for the Censored Data 253
Model Building 255
Distribution of the Explanatory Variables 256
Confounding 256
Interaction Effects 256
Nonlinearity 256
Model Selection 256
Collinearity 256
Multiple Comparisons 257
Missing Data 257
Linear Mixed-Effects Models (Clustered or Longitudinal Studies) 258
Conclusion 259
References 260

15. Good Clinical Practice and Good Laboratory Practice

Nathalie K. Zgheib, Stephanie L. Tomasic and Robert A. Branch

Overview 262
Good Clinical Practice 262
Introduction 262
Definition 262
Rules and Regulations 262
Clinical Practice and Research 263
Key Participants in Clinical Research 265
Documentation and Record Keeping 270
Data Management and Presentation 271
Monitoring and Compliance 271
Conclusion 272
Good Laboratory Practice 272
Introduction 272
Definition and Scope 272
Organization and Personnel 273
Management of the Testing Facility 273
Quality Assurance 274
Test, Reference, and Control Articles 275
Protocol for and Conduct of a Nonclinical Laboratory Study 275
Reporting of Nonclinical Laboratory Study Results 276
Record Keeping 276

Disqualification of Laboratory Facility Resources 276
Conclusion 277
Glossary 277
List of Acronyms and Abbreviations 277
References 277

Section III
Human Genetics

16. Introduction to Human Genetics

Bruce R. Korf

Introduction 282
Basic Molecular Genetics 282
DNA Structure 282
DNA Replication 283
Transcription 283
Translation 285
Chromosome Structure and Function 286
Mitosis and Meiosis 287
Gametogenesis 288
Patterns of Genetic Transmission 288
Single Gene Inheritance (Mendelian Inheritance) 289
Non-Mendelian Inheritance 291
Multifactorial Inheritance (Polygenic Inheritance) 295
Cytogenetics and Chromosomal Disorders 295
Methods of Chromosomal Analysis 295
Chromosomal Abnormalities 296
The Human Genome 298
Structure and Organization of the Genome 298
Genetic Variation 299
Mutation and Polymorphism 299
Genotype–Phenotype Correlations 302
Medical Applications 303
Molecular Diagnostic Testing 303
Therapy of Genetic Disease 306
Genetic Counseling 308
Phenotyping and Clinical Research 309
Genotype–Environment Interaction 309
Phenotypic Complexity 310
Approaches to Gene Discovery 310
Conclusion 311
References 311
Bibliography 311

17. Epidemiologic and Population Genetic Studies

Angela J. Rogers and Scott T. Weiss

Introduction 314
Design Issues in Genetic Association Studies 315
Population Issues: Defining a Phenotype and Selecting Epidemiologic Study Design 315
Epidemiologic Study Design 316
Case–Control Studies 316
Cohort or Population Studies 316
Family-Based Studies 317
Comparison of Family-Based Versus Case–Control Studies 317
Genetic Study Design: Genome-Wide Association Study Versus Hypothesis-Driven (Candidate Gene) Approaches 317
Hypothesis-Free Testing: Genome-Wide Association Study 318
Candidate Gene or Region-Based Testing, With a Focus on SNP Selection 318
Interpreting Results of Genetic Association Studies 319
Genotype Quality Control 320
Correction for Multiple Comparisons 321
Population Stratification 322
Power 323
Future Directions 324
Emerging Biologic Targets 324
Integrative Statistical Approaches 325
From Association to Functional Variant 325
Conclusion 325
References 325

18. Pharmacogenetics of Drug Metabolism

Zeruesenay Desta and David A. Flockhart

Introduction 327
Pharmacogenetics of Drug Metabolism: Historical Aspects 328
Genetic Polymorphisms of Individual Drug-Metabolizing Genes 329
CYP1A2 329
CYP2B6 330
CYP2C8 332
CYP2C9 333
CYP2C19 335
CYP2D6 336
CYP3A5 338

N-acetyltransferase 2 340
Thiopurine Methyltransferase 340
UDP-Glucuronosyltransferase 341
Butyrylcholinesterase 342
Conclusions 343
References 343

19. **Statistical Techniques for Genetic Analysis**

Jessica Lasky-Su

Introduction 348
Genetic Determination of Complex Disease 348
Twin Studies 348
Family Studies 348
Adoption Studies 348
Genetic Linkage Studies 349
Common Genetic Study Designs and Statistical Tests 349
Case–Control Studies 350
Population-Based Studies 350
Family-Based Association Studies 351
Genomewide Association Studies 351
Population Stratification Adjustment 352
Multiple Testing Adjustment 352
Next-Generation Sequencing 354
Rare Genetic Variant Analysis 354
Metaanalysis Techniques 355
Gene-By-Environment Analysis 355
Multivariant Approaches 356
Multiple Regression Analyses 356
Discrimination Methods 356
Network Medicine 356
Basic Network Theory 356
Correlation Coexpression Networks 357
Pathway Analyses 357
Integrative Omics 358
Phenotypic Limitations 359
Computer Programs 359
Summary and Conclusions 359
Glossary 359
List of Acronyms and Abbreviations 360
References 360

Section IV
Human Pharmacology

20. **Introduction to Clinical Pharmacology**

Rommel G. Tirona and Richard B. Kim

Introduction: Mechanisms of Drug Disposition and Interactions 366
Transporters and Drug Absorption, Distribution, and Excretion 366
Intestinal Transporters 368
Hepatic Transporters 368
Renal Transporters 369
Drug-Metabolizing Enzymes 370
CYP2C9/CYP2C19 371
CYP2D6 371
CYP3A4/CYP3A5 372
Drug–Drug Interactions 372
Clinically Important Drug-Metabolism–Associated Interactions 372
Transporters and Drug Interactions 373
Induction and Regulation of Drug-Metabolizing Enzymes and Transporters 373
Principles of Pharmacokinetics 375
Introduction to Pharmacokinetics 375
Pharmacokinetic Concepts 375
Dose Selection 381
Intermittent Dose Administration 382
Conclusion 383
References 383

21. **Adverse Drug Events**

Dan M. Roden

The Multifactorial Nature of Adverse Drug Events 389
Types of Adverse Drug Events 390
System Errors 390
Linking Events to Drug Administration—the "Easy" Examples 390
Linking Events to Drug Administration—the "Hard" Examples 390
Adverse Drug Events Due to Aberrant Drug Disposition (Variable Pharmacokinetics) 391
Adverse Drug Events Not Due to Elevated Drug or Metabolite Concentrations 393
Genetics to Genomics 394
References 394

Section V
Societal Context of Human Research

22. **Translating Science to the Bedside: The Innovation Pipeline**

Seema Basu

Realities of the Marketplace 400
What Are the Phases Involved in Taking Ideas/Discoveries to the Patient's Bedside? What Are the Critical Issues to Consider at Each Phase? 402

How Does This Differ for Various Types of Technology? What Are the Market Pressures for Devices, Software, Diagnostics, Therapeutics, and Research Tools? 402
What Funding Sources Support Development and Creation of Products and Services? 403
What Are the Roles of Government, Philanthropy, and Industry? 403
Types of Relationship: Sponsored Research, Grants, Codevelopment, and Gifts 403
What Resources Are Available at Academic Health-Care Systems to Help Translational Researchers Bring Products and Technologies to Market for Patient Benefit? 404
Ideas and Innovations 404
What Is Intellectual Property? 404
Why Are Patents and Copyrights Important? 406
Working With Industry 407
The Academic Health-Care System as a "Living Laboratory" 407
Common Challenges 409
Entrepreneurship 410
Market Opportunity: What Problem Am I Solving? 410
Technology: What Is the Status of the Core Technology? 410
Financial: How Much Money Will It Take to Get This Idea to Market? Where Will It Come From? 411
Management: How Do I Think About the Right People, Skills, and Change of Control? 412
Legal and Regulatory Affairs: What Kind of Help Do Entrepreneurs Need at the Early Stages? 412
Clinical Evaluation of Innovative Products 413
How Does Clinical Evaluation Differ From Earlier Stages of Innovation? 413
How Is the Complex Relationship Between Safety and Innovation Managed? 413
What Are the Role and Responsibilities of the Principal Investigator? 413
What Are the Roles and Responsibilities of the Sponsor? 414
What Is the Role and Responsibility of the Food and Drug Administration? 414
How Do Academic Health Centers Support and Guide These Roles? 415
Why Is a Clinical Trial Agreement Needed? 415
How Do I Get Started? 416
Conflicts of Interest 416
What Are Conflicts of Interest? 416
Required Components of Conflict of Interest Policies 417
Translating Science to the Bedside Cores in Academic Health Centers 419
How the Innovation Office Help Partners HealthCare Researchers 419
Summary 421
Statutes and Federal Regulations 421
Cases 421
Endnotes 421
References 421

23. Regulatory Environment

Christine Nguyen, Audrey Gassman and Hylton V. Joffe

Introduction 423
The US Food and Drug Administration 424
Overview 424
Organization 424
Legal Authority 425
Nonclinical Testing 426
The Investigational New Drug Application 427
The Marketing Application 433
Expanded Regulatory Authority on Postmarket Drug Safety 435
Other Regulatory Agencies 436
Conclusions 436
Glossary 436
List of Acronyms and Abbreviations 437
Acknowledgments 437
References 438

24. Ethical Issues in Translational Research and Clinical Investigation

Greg Koski

Introduction 442
The Ethical Dimension of Scientific Inquiry 442
Responsibility in Science and Society 443
Responsibilities of Scientists 443
Societal Responsibilities 443
Ethics and Translational Research 443
Guiding Principles for the Responsible Translational Investigator 445
Beyond Ethics: Regulations, Compliance, and Professionalism in Translational Research 446
Justice, Beneficence, and Respect for Persons: From Principles to Practice 447
Research Risks, Harm, and Injury 447
Benefits 448
Special Populations 448
Issues in Collection of DNA and Other Biospecimens for Research 448
Regulation of Research and Protection of Subjects 449
Research and Regulations in the United States 449

Nongovernmental Agencies and Associations 451
Public Perception of Clinical Research 452
Protection of Human Subjects 452
Review and Oversight 452
Institutional Review Boards and Ethics Committees 453
Data and Safety Monitoring Boards, Medical Monitors, and Subject Advocates 453
Medicolegal Framework, Liability, and Risk Management 453
Individuals and the Clinical Research Process 454
Motivation and Expectations of the Volunteer Subject 454
Motivation of the Scientist and Conflicts of Interest 455
Professionalism in Clinical Research 455
References 456

25. **Clinical Research in the Public Eye**

Mary Woolley

Introduction 457
The Cultural Context of Research 459
The Lens of Health and Health Care 459
Shifting Power to the Patient 459
Public Input and National Institutes of Health 460
Public Perception of Research 460
Privacy Issues 462
The Internet and an Empowered Public 465
Continuing Challenges 466
Electronic Media Technology Changes Everything 466
Research Information and the News Media: Scientists' Role 467
The Celebrity Factor 468
Unrealistic Expectations? 468
Science and Politics 469
The Small Voice of Science: Stepping Up to Strengthen It 469
The Role and Influence of the White House 470
How Congress Influences Medical Research 471
Making the Case for Research to Congress 472
The Role and Influence of Patient Advocacy Organizations 472
The Role and Influence of Philanthropy 473
Public-Private Collaboration 473
Conclusion 474
Acknowledgment 475
References 475

Section VI
Research in Special Populations

26. **Research in Special Populations: Acute Illnesses; Critical Care; and Surgical Patients**

Todd W. Rice and Gordon R. Bernard

Introduction 482
Trial Design 482
Type of Study 482
Selecting a Control Group 483
Placebo-Controlled Studies in Surgical Patients or Nonsurgical Invasive Procedures 484
Usual Care in Critically Ill Patients 485
Studies Comparing Usual Care Components 485
Protocolized Nonstudy Treatment 486
Informed Consent 488
Surrogate Informed Consent 489
Waiver of Consent in Emergency Research 490
Outcomes 490
Associated Versus Attributable Outcomes 490
Endpoints 491
Adverse Events 495
Conclusion 496
References 496

27. **Research in the Emergency Care Environment**

James Quinn and Daniel J. Pallin

Introduction 501
The Environment and Unique Challenges of Emergency Care Research 501
Examples of Early Success 502
Building an Emergency Care Research Site 503
Funding of Infrastructure in the Emergency Care Environment 504
The Role of Industry 505
Implementation of Emergency Care Research 506
Recruitment 506
Trial Design Considerations 508
Retention of Patients and Strategies to Enhance Follow-Up 510
Conclusion 510
References 511

28. Psychiatric Disorders

Alan F. Schatzberg

Introduction 515
Diagnostic Issues 515
Adults 515
Special Age- and Gender-Based Populations 516
Types of Studies 517
Epidemiological 517
Observational 517
Mechanism and Physiology 517
Disease Mechanisms 518
Treatment 518
Translational Research 518
Tools 519
Behavioral Measures 519
Biological Measures 519
Imaging 523
Genetics 523
Statistical and Design Issues 524
Power 524
Predictors and Moderators 524
Special Issues 525
Treatment Studies 525
Behavioral Research in Medical Disorders 527
A Practical Schematic Approach 528
Summary 530
References 530

29. Research in Special Populations: Geriatrics

Stephanie Studenski and Luigi Ferrucci

Introduction 533
What Is Different About Aging Research? 534
Disease and Aging 534
A Conceptual Model to Account for the Causes and Consequences of Altered System Structure and Function With Aging 534
The Effect of Aging on Practical Aspects of Clinical Research 537
How an Aging Perspective Affects Research Topics and Approaches 538
Overview 538
Translational Research 538
Clinical Trials 539
Population-Based Research 542
The Effect of Aging on the Pragmatics of Research 543
Overview 543
Samples 545
Measures 546
Important Measures for Aging Populations 547
Interventions 547
Analysis 547
Conclusions and Recommendations 550
References 550

30. Clinical Research in Neurology

Keren Regev and Howard L. Weiner

Introduction 555
Features Unique to Neurologic Diseases 556
The Challenges 556
Disease Examples 558
Multiple Sclerosis 558
Alzheimer Disease 561
Amyotrophic Lateral Sclerosis 564
Glioma 566
Acute Ischemic Stroke 567
Conclusion 568
References 568

31. Research in Pediatrics

Lisa Bomgaars, Stacey Berg and Ann R. Stark

Introduction 573
What Is Different About Pediatric Research? 574
Developmental Physiology 574
Limitations Related to Body Size 576
Orphan (Rare) Diseases 576
Population Available for Study Is Smaller in Children Than in Adults 576
Small Numbers Mean Multicenter Trials Are Usually Required 576
Lack of Pediatric Guidelines for Most Drugs 577
Need for Very Long-Term Follow-up to Determine Outcomes 578
Pediatric Conditions as Focus of Inquiry 579
Prematurity 579
Childhood Cancers That Do Not Occur in Adults 580
Regulatory and Ethical Environment for Pediatric Research 580
Risk Categories 581
Assent/Permission Procedures 581
Conclusion 582
Statutes and Regulations 582
Cases 583
References 583

32. Cancer as a Paradigm for Translational and Clinical Biomedical Research

César Serrano and George D. Demetri

Introduction 588
Cancer: From the Edwin Smith Papyrus to the Molecular Genetic Era 588
Defining Subgroups in Cancer 589

A Genetic Definition of Cancer 590
Translation of Cancer Gene Expression Profiling to the Clinic 592
Massive Parallel DNA Sequencing: Deciphering the Complexity of Cancer 593
Cancer Drivers and Personalized Medicine 596
Targets in Cancer Therapy 596
From the Bench to the Bedside 598
Biomarkers and Clinical Trials 599
Current Strategies in Molecular Targeted Therapy 600
The Crusade to Overcome Drug Resistance in Cancer 601
Tumor Heterogeneity 601
Mechanisms of Resistance to Targeted Therapies and Future Perspectives in Drug Development 602
List of Acronyms and Abbreviations 603
References 604

33. **Maintaining an Emphasis on Rare Diseases With Research Initiatives and Resources at the National Center for Advancing Translational Sciences**

Stephen C. Groft and Rashmi Gopal-Srivastava

Introduction 609
Translational Science Spectrum 610
Definition of Rare Diseases 610
International Classification of Diseases 611
Evolving Approaches to Rare Diseases Research 612
Importance of Genomewide Association Studies 612
Team Approach 612
Translational Research Efforts and Resources at NCATS and Other NIH Institutes 613
The Rare Diseases Clinical Research Network Program—A Model for Collaboration 613
Rare Diseases Research and Orphan Product Development 613
RDCRN and Clinical and Translational Science Awards Programs on Education and Training Resources 614
Assessment of Unmet Medical Device Needs for Rare Diseases 615
An Even Brighter Path Forward 615
References 616

Section VII
Infrastructure

34. **Clinical and Translational Science Infrastructure**

David Robertson and Gordon H. Williams

Introduction 620
Reinventing the Clinical Research Infrastructure 620
Clinical and Translational Science Institutes 622
National Center for Advancing Translational Sciences 623
NCATS, CTSA, and Clinical Trial Recruitment Innovation 623
NCATS' Major Programs and Mission 624
NCATS' Innovative Technological Programs 625
NCATS' Rare Diseases Clinical Research Network 625
Human Genome Project 625
Clinical and Translational Science Award 626
Structural Components of CTSA 626
Scientific Review 628
Collective Initiatives of the CTSA Consortium 630
Conclusion 632
References 632

Section VIII
Education, Training and Career Choices

35. **Education, Training and Career Choices: Training Basic, Clinical, and Translational Investigators**

Katherine E. Hartmann, Elizabeth Heitman and Nancy J. Brown

Introduction 637
Overview 638
Didactic Curriculum 639
Core Competencies Common to all Types of Research 639
Core Competencies for T-1 Translational Research 641
Core Competencies for Epidemiologic, Health Outcomes and T-2 Translational Research 642
Degree-Granting Programs in Clinical or Translational Research 644
The Mentored Research Experience 646
Qualities of a Good Mentor 646

Using a Mentor Effectively 646
The Mentorship Committee 646
Career Development Resources 647
Funding for Training Clinical and Translational Investigators 647
Further Reading 647

36. A Stepwise Approach to a Career in Translational Research

William F. Crowley Jr.

Definitional Issues 649
Historical Perspective 650
Step 1: The Starting Point 651
Step 2: The Need for Normative Data and Control Populations 652
Step 3: Engaging Relevant Basic Researchers and Their Technologies 652
Step 4: Identifying Tractable Problems 653
Step 5: Identifying Appropriate Mentors Across a Career 653
Step 6: Obtaining Successful Independent Funding 654
Step 7: The Perils of Senior Leadership 654
Summary 655
References 655

37. Physician Careers in the Pharmaceutical Industry

Ronald L. Krall

Introduction 658
Medical-Scientific Positions in the Pharmaceutical Industry 659
Experimental or Translational Medicine 659
Clinical Pharmacology 660
Clinical Research Physician 660
Medicine Safety and Pharmacovigilance 661
Medical Affairs 663
Regulatory Affairs/Regulatory Science 663
Pharmacoepidemiology and Health Outcomes Research 664
Project Leadership 664
Management 665
Medical Officer: Decisions That Require Medical Input 665
A Pharmaceutical Career 666
Summary 666
References 666

Section IX
Research in Academia

38. Industry-Sponsored Clinical Research in Academia

Italo Biaggioni

Introduction 671
The Public Perspective 672
The Academic Health Center Perspective 672
The Industry Perspective 673
The Investigators' Perspective 674
Matching Industry Needs and Academic Health Center Priorities 674
Academic Clinical Trials Centers As a Solution 675
Financing Clinical Trial Centers 675
Information Technology Solutions to Improve Patient Enrollment 676
Conclusion 676
Acknowledgment 677
References 677

39. Governmental Support of Research

Sten H. Vermund and Salim Abdool Karim

Introduction 680
Overview 680
United States Government Scientific Programs 681
The National Institutes of Health 684
The Centers for Disease Control and Prevention 689
Scientific Programs in Europe, Canada, and Australia/New Zealand 690
The European Community 690
National Initiatives 692
Scientific Programs in Asia, Africa and South/Central America and the Caribbean 693
The South African Medical Research Council 693
Balancing the Needs of Intramural and Extramural Research Units 696
Supporting Capacity Building Through Grants and Scholarships 697
New Initiatives to Recognize and Support Scientific Merit 697
Current Support for Clinical and Translational Research 697
Conclusion 699